2. Search Result
Search Result
Results for "

Hepatocellular carcinoma tumor

" in MedChemExpress (MCE) Product Catalog:

113

Inhibitors & Agonists

1

Screening Libraries

3

Biochemical Assay Reagents

12

Peptides

9

Inhibitory Antibodies

21

Natural
Products

2

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-N7073
    Silymarin
    5+ Cited Publications

    		 SARS-CoV Infection Neurological Disease Inflammation/Immunology Cancer
    Silymarin is an extract of the milk thistle (Silybum marianum). Silymarin is an effective SARS-CoV-2 main protease (M pro) inhibitor. Silymarin can significantly reduce tumor cell proliferation, angiogenesis as well as insulin resistance. Silymarin has the chemopreventive effect on hepatocellular carcinoma (HCC). Silymarin has the potential for COVID-19 research .
    Silymarin
  • HY-N0484
    Liensinine
    Maximum Cited Publications
    20 Publications Verification

    		 Reactive Oxygen Species (ROS) Autophagy Apoptosis VEGFR JAK Amyloid-β p38 MAPK HIF/HIF Prolyl-Hydroxylase STAT PI3K JNK Akt Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
    Liensinine is a bisbenzylisoquinoline alkaloid. By inhibiting the PI3K/AKT and JNK/p38-MAPK signaling pathways, Liensinine suppresses autophagy and apoptosis, clears Aβ, and exerts anti-inflammatory, antioxidant and neuroprotective effects. Liensinine activates AMPK and inhibits the expression of HIF-1α and VEGF, thereby suppressing angiogenesis. Liensinine exerts anti-tumor effects through ROS-mediated inhibition of the JAK2/STAT3 signaling pathway. Liensinine can be used for the research of diseases such as Alzheimer's disease, hepatocellular carcinoma, osteosarcoma, sepsis-induced organ injury and stroke .
    Liensinine
  • HY-N0462
    Corilagin
    5+ Cited Publications

    NP-004255

    		 Toll-like Receptor (TLR) Reverse Transcriptase Bacterial Apoptosis Autophagy Infection Inflammation/Immunology Cancer
    Corilagin, a gallotannin, has anti-tumor, anti-inflammatory and hepatoprotective activities. Corilagin inhibits activity of reverse transcriptase of RNA tumor viruses. Corilagin also inhibits the growth of Staphylococcus aureus with a MIC of 25 μg/mL. Corilagin shows anti-tumor activity on hepatocellular carcinoma and ovarian cancer model. Corilagin shows low toxicity to normal cells and tissues .
    Corilagin
  • HY-100492
    Fisogatinib
    5 Publications Verification

    BLU-554

    		 FGFR Cancer
    Fisogatinib (BLU-554) is a potent, highly selective and orally active fibroblast growth factor receptor 4 (FGFR4) inhibitor with an IC50 of 5 nM. Fisogatinib has significant anti-tumor activity in models of hepatocellular carcinoma (HCC) that are dependent on FGFR4 signalling .
    Fisogatinib
  • HY-P99013
    Codrituzumab
    1 Publications Verification

    GC33; RO5137382

    		 Glycoprotein VI Cancer
    Codrituzumab (GC33) is a humanized monoclonal antibody targeting human GPC3 (glypican-3), with high affinity (Kd of 0.673 nM). GPC3 is an oncofetal protein expressed on the cell surface of hepatocellular carcinoma (HCC). Codrituzumab induces antibody-dependent cellular cytotoxicity (ADCC) and inhibits tumor growth .
    Codrituzumab
  • HY-P99052
    Tislelizumab
    3 Publications Verification

    BGB-A317

    		 PD-1/PD-L1 Inflammation/Immunology Cancer
    Tislelizumab is a monoclonal antibody that specifically binds to programmed cell death receptor 1 (PD-1), blocking its interaction with programmed death ligand 1 (PD-L1) and programmed death ligand 2 (PD-L2). Tislelizumab can reactivate immune cells such as T lymphocytes and enhance anti-tumor activity. Tislelizumab can be used for the research of a variety of tumors including typical Hodgkin's lymphoma, urothelial carcinoma, non-small cell lung cancer and hepatocellular carcinoma .
    Tislelizumab
  • HY-111126
    K67
    1 Publications Verification

    		 p62 Keap1-Nrf2 Cancer
    K67 is a selective the interaction between Keap1 and S349 phosphorylated p62 inhibitor, with an IC50 of 1.5 μM. K67 has a weaker inhibitory effect on the interaction between Keap1 and Nrf2 (IC50 is 6.2 μM). K67 competitively binds to the binding site of Keap1 with p-p62, blocking the abnormal activation of the p62-dependent Nrf2 pathway. K67 inhibits tumor cell proliferation and enhances the sensitivity of hepatocellular carcinoma (HCC) to chemotherapeutic drugs by restoring Keap1-mediated ubiquitination and degradation of Nrf2 .
    K67
  • HY-178018
    D574-0246

    iOXCT1

    		 Mitochondrial Metabolism Cancer
    D574-0246 is a dual-activity inhibitor of OXCT1, inhibiting both the ketolytic and succinyltransferase activities of OXCT1. D574-0246 reduces substrate-specific (LACTB K284) and global protein succinylation and decreases OXCT1 ketolytic activity in HepG2 cells. D574-0246 inhibits the viability of HCC cells (IC50: 16.49 μM in PLC cells, 6.656 μM in HepG2 cells). D574-0246 exerts anti-tumor efficacy in nude mice bearing OXCT1-overexpressing HepG2 xenograft tumors. D574-0246 can be used for the study of hepatocellular carcinoma (HCC) .
    D574-0246
  • HY-P5133
    Synstatin (92-119)
    1 Publications Verification

    SSTN92-119

    		 Integrin Cancer
    Synstatin (92-119) is an inhibitor of αvβ3/αvβ5 integrins and IGF1R with anti-angiogenic, anti-proliferative, antioxidant and anti-tumor activities. Synstatin (92-119) competitively blocks the capture of αvβ3/αvβ5 integrins and IGF1R by syndecan-1, disrupts the formation of the syndecan-1 : integrin : IGF1R ternary complex, inhibits integrin activation and talin-mediated signaling pathways, and blocks VEGF-induced angiogenesis. Synstatin (92-119) is applicable to research related to cancer and hepatocellular carcinoma .
    Synstatin (92-119)
  • HY-150072
    DS89002333

    		PKA Cancer
    DS89002333 is an orally active and potent PRKACA inhibitor, with an IC50 of 0.3 nM. DS89002333 shows good anti-tumor activity in an FL-HCC patient-derived xenograft model (expressing the DNAJB1-PRKACA fusion gene). DS89002333 can be used in study of fibrolamellar hepatocellular carcinoma (FL-HCC) .
    DS89002333
  • HY-N0864
    Macranthoidin B

    Macranthoiside I

    		 Apoptosis COX Reactive Oxygen Species (ROS) Caspase SOD Cancer
    Macranthoidin B (Macranthoiside I) is an orally active triterpene saponin. Macranthoidin B inhibits epithelial-mesenchymal transition in endometriosis via the COX‑2/PGE2 pathway, and also induces tumor cell apoptosis and inhibits their proliferation by regulating metabolism and increasing ROS levels . Macranthoidin B can be used in studies related to endometriosis, colorectal cancer and hepatocellular carcinoma .
    Macranthoidin B
  • HY-160215
    GFH018

    		TGF-β Receptor p38 MAPK TGF-beta/Smad Interleukin Related Cancer
    GFH018 is an orally active, selective and ATP-competitive TGF-βR1 inhibitor with an IC50 of 40 nM. GFH018 reactivates the immune system by blocking the immunosuppression mediated by regulatory T cells and M2 macrophages. GFH018 inhibits tumor angiogenesis. GFH018 suppresses tumor growth in mouse tumor models. GFH018 can be used for the research of solid tumors, hepatocellular carcinoma, colorectal cancer, breast cancer, and relapsed/metastatic nasopharyngeal carcinoma .
    GFH018
  • HY-P11099
    Cys-LT7

    		Transferrin Receptor Neurological Disease Cancer
    Cys-LT7 is a transferrin receptor (TfR)-targeting peptide ligand. Cys-LT7 binds to a TfR site distinct from endogenous transferrin, mediates conjugated Doxorubicin (HY-15142A) delivery to TfR-overexpressed tumor cells, and exhibits low toxicity to TfR-low-expressed normal cells. Cys-LT7 is an L-configuration peptide susceptible to proteolytic enzymes, leading to poor biostability in peptide-drug conjugates. Cys-LT7 can be used for the research of glioblastoma, hepatocellular carcinoma, lung carcinoma .
    Cys-LT7
  • HY-N0754
    Eupalinolide A

    		YAP HSP Reactive Oxygen Species (ROS) ERK Autophagy Apoptosis Tyrosinase DNA/RNA Synthesis Neurological Disease Inflammation/Immunology Cancer
    Eupalinolide A is a Yes-associated protein (YAP) degrader and HSP70 inducer. Eupalinolide A inhibits osteogenic differentiation of tendon-derived stem cells (TDSCs). Eupalinolide A induces autophagy in hepatocellular carcinoma cells via activating the ROS/ERK signaling pathway. Eupalinolide A protects PAM212 cells from UVB-, Menadione (HY-B0332)-, or heat shock-induced apoptosis. Eupalinolide A alleviates trauma-induced heterotopic ossification (HO) of Achilles tendon and inhibits growth of MHCC97-L and HCCLM3 hepatocellular carcinoma xenograft tumors in mice. Eupalinolide A can be used for the study of traumatic heterotopic ossification of tendons and hepatocellular carcinoma .
    Eupalinolide A
  • HY-N2232
    N-​Feruloyloctopamine

    N-trans-Feruloyloctopamine

    		 Akt p38 MAPK Apoptosis Cadherin Cancer
    N-Feruloyloctopamine (N-trans-Feruloyloctopamine) is an antioxidant component that can be isolated from garlic skin. N-Feruloyloctopamine can inhibit tumor cell proliferation and invasion, and induce apoptosis. N-Feruloyloctopamine has antitumor activity and can be used in the research of tumors such as hepatocellular carcinoma .
    N-​Feruloyloctopamine
  • HY-135644
    Rencofilstat
    1 Publications Verification

    CRV431

    		 Cyclophilin Sirtuin Nuclear Factor of activated T Cells (NFAT) Interleukin Related Cancer
    Rencofilstat (CRV431) is an orally active pan-cyclophilin inhibitor with IC50 values of 2.5 nM, 3.1 nM, 2.8 nM, 7.3 nM for Cyp A, CypB, Cyp D and Cyp G, respectively. Rencofilstat reduces fibrosis and tumor growth in models of chronic liver disease. Rencofilstat can be used for the study of nonalcoholic steatohepatitis (NASH), hepatocellular carcinoma and viral hepatitis-induced liver disease .
    Rencofilstat
  • HY-P99159
    Ivuxolimab

    		Interleukin Related Cancer
    Ivuxolimab is a fully human IgG2 agonist targeting OX40 (CD134), which selectively binds to the OX40 receptor on the surface of activated CD4 + and CD8 + T cells without inducing antibody-dependent cytotoxicity. Ivuxolimab can promote T cell proliferation, survival and cytokine (such as IFN-γ, IL-2) secretion, inhibit regulatory T cell function, and enhance anti-tumor immune response. Ivuxolimab can be used in the study of melanoma, hepatocellular carcinoma, head and neck squamous cell carcinoma, etc .
    Ivuxolimab
  • HY-B1817A
    Zinc acetate, 99.99% trace metals basis

    Zinc(II) acetate, 99.99% trace metals basis

    		 CDK Heme Oxygenase (HO) Apoptosis Others
    Zinc (Zinc (II)) acetate, 99.99% trace metals basis is a heme oxygenase 1 (HO-1) activator and apoptosis inducer with cytotoxic and anticancer activities. Zinc acetate, 99.99% trace metals basis enhances HO-1 expression, alters the microRNA profile, and increases the level of caspase-cleaved cytokeratin 18. Zinc acetate, 99.99% trace metals basis also regulates the expression of Cdk2/cyclin E and interferes with cell cycle progression. Zinc acetate, 99.99% trace metals basis effectively inhibits cancer cell proliferation and induces their rapid death, with no significant cytotoxicity to non-tumor tissues. Zinc acetate, 99.99% trace metals basis has been widely used in studies related to hepatocellular carcinoma, prostate cancer, and other conditions .
    Zinc acetate, 99.99% trace metals basis
  • HY-Y0496
    1,4-Dichlorobenzene

    		Insecticide Environmental Pollutants Mitosis Cancer
    1,4-Dichlorobenzene is a non-genotoxic, orally active mitogenic/tumor-promoting carcinogen that is also widely used as a dye, resin intermediate, and deodorant, moth repellent/insecticide. 1,4-Dichlorobenzene induces liver tumors in mice and promotes the growth of spontaneous precancerous lesions, but shows no liver tumor-inducing activity in F344 rats. Exposure to 1,4-dichlorobenzene leads to elevated leukocyte counts, serum alanine aminotransferase, and blood urea nitrogen levels. Due to the hepatotoxic characteristics, 1,4-Dichlorobenzene is applicable to liver cancer-related research .
    1,4-Dichlorobenzene
  • HY-153863
    MS934

    		PROTACs MEK Raf Cancer
    MS934 is a novel improved VHL-recruiting MEK 1/2 PROTAC degrader. MS934 also degrades CRAF. MS934 can be used for the research of variety of human cancers, such as melanoma, nonsmall cell lung cancer (NSCLC), colorectal cancer, primary brain tumors, and hepatocellular carcinoma (Pink: Target protein ligand (HY-168288); Black: linker (HY-168289); Blue: E3 ligase ligand (HY-112078)) .
    MS934
  • HY-N6623
    Malvidin-3-galactoside chloride
    1 Publications Verification

    		 Apoptosis Endogenous Metabolite Reactive Oxygen Species (ROS) Cancer
    Malvidin-3-galactoside chloride, an anthocyanin monomer, induces hepatocellular carcinoma (HCC) cells cycle arrest and apoptosis. Malvidin-3-galactoside chloride inhibits the production and accumulation of ROS. Malvidin-3-galactoside chloride has anti-tumor function .
    Malvidin-3-galactoside chloride
  • HY-P11228
    FPP29

    		PROTACs Apoptosis DNA/RNA Synthesis Cancer
    FPP29 is a potent peptide-based FOXM1 PROTAC degrader. FPP29 induces ubiquitination and degradation of FOXM1. FPP29 inhibits FOXM1 via the ubiquitin-proteasome degradation pathway. FPP29 induces Apoptosis. FPP29 suppresses tumor growth in hepatocellular carcinoma xenograft models. FPP29 can be used in the research of hepatocellular carcinoma (cell-penetrating peptide: (HY-P0133); VHL ligase ligand: (HY-P11493); linker: (HY-W013664); FOXM1 ligand: (HY-P11494)) .
    FPP29
  • HY-N12445
    Quercetin-3'-O-glucoside
    1 Publications Verification

    		 Topoisomerase Caspase Apoptosis SOD Metabolic Disease Inflammation/Immunology Cancer
    Quercetin-3'-O-glucoside is an orally active flavonoid glycoside. Quercetin-3'-O-glucoside reduces liver glucose-6-phosphatase activity, alters serum insulin and glucose levels, and regulates the activities of antioxidant enzymes in the liver and kidney. Quercetin-3'-O-glucoside inhibits DNA topoisomerase II, induces S-phase cell cycle arrest and caspase-3-mediated apoptosis in hepatocellular carcinoma cells. Quercetin-3'-O-glucoside selectively inhibits EGFR-mediated signaling pathways targeting AKT, ERK1/2, FAK and MEK1/2. Quercetin-3'-O-glucoside inhibits growth factor-induced migration and invasion in pancreatic cancer cells. Quercetin-3'-O-glucoside exerts free radical scavenging effects. Quercetin-3'-O-glucoside is applicable to research related to pancreatic cancer, diabetes, hepatocellular carcinoma and malignant tumors .
    Quercetin-3'-O-glucoside
  • HY-115581A
    Thymidine 3',5'-diphosphate tetrasodium

    Deoxythymidine 3′,5′-diphosphate tetrasodium; pdTp tetrasodium

    		 Apoptosis MicroRNA Cancer
    Thymidine 3',5'-diphosphate (Deoxythymidine 3′,5′-diphosphate) tetrasodium is a selective inhibitor of staphylococcal nuclease and tudor domain containing 1 (SND1, the MicroRNA regulatory complex RISC subunit) and [3,5- 2H2] tyrosyl nuclease. Thymidine 3',5'-diphosphate tetrasodium has anti-tumor activity and can also be used as a catalyst in biochemical reactions .
    Thymidine 3',5'-diphosphate tetrasodium
  • HY-175646
    AGPAT4-IN-1

    		Acyltransferase mTOR Ribosomal S6 Kinase (RSK) Apoptosis Cancer
    AGPAT4-IN-1 (Compound CL26) is a covalent AGPAT4 inhibitor with an IC50 of 795 nM. AGPAT4-IN-1 covalently binds to AGPAT4 at Cys 228 and significantly inhibits acyltransferase activity, LPA-to-PA conversion and downstream mTOR/S6K pathways. AGPAT4-IN-1 sensitizes hepatocellular carcinoma (HCC) tumors to Sorafenib (HY-10201) and significantly induces apoptosis with a synergistic response. AGPAT4-IN-1 has antitumor activity and reduces tumorigenicity and stemness in HCC xenograft mouse models .
    AGPAT4-IN-1
  • HY-W011434
    Triglycidyl isocyanurate

    TGIC

    		 MDM-2/p53 Apoptosis Inflammation/Immunology Cancer
    Triglycidyl isocyanurate (TGIC; Teroxirone) is a triazene triepoxide with antiangiogenic and antineoplastic activities. Triglycidyl isocyanurate inhibits the growth of non-small-cell-lung cancer cells via?p53 activation. Triglycidyl isocyanurate induces cell apoptosis. Triglycidyl isocyanurate can be used for cancer research .
    Triglycidyl isocyanurate
  • HY-113081R
    1-Methyladenosine (Standard)

    		Reference Standards Endogenous Metabolite PPAR Hedgehog Cancer
    1-Methyladenosine (Standard) is the analytical standard of 1-Methyladenosine. This product is intended for research and analytical applications. 1-Methyladenosine is an RNA modification that can serve as a tumor marker, with elevated levels in the body associated with cancer development. Following 1-methyladenosine methylation, upregulation of PPARδ expression regulates cholesterol metabolism and activates Hedgehog signaling pathway, driving liver tumorigenesis . In Vitro:Compared to surrounding tumor tissues, 1-methyladenosine methylation in RNA is aberrantly elevated in hepatocellular carcinoma (HCC) cell lines and liver cancer stem cells (CSCs). Methylated 1-methyladenosine can promote cholesterol synthesis and activate the Hedgehog signaling pathway by enhancing the translation of PPARδ in liver CSCs, ultimately driving the self-renewal and tumorigenesis of liver cancer stem cells .
    1-Methyladenosine (Standard)
  • HY-N0462R
    Corilagin (Standard)

    NP-004255 (Standard)

    		 Toll-like Receptor (TLR) Reference Standards Reverse Transcriptase Bacterial Apoptosis Autophagy Infection Inflammation/Immunology Cancer
    Corilagin (Standard) is the analytical standard of Corilagin. This product is intended for research and analytical applications. Corilagin, a gallotannin, has anti-tumor, anti-inflammatory and hepatoprotective activities. Corilagin inhibits activity of reverse transcriptase of RNA tumor viruses. Corilagin also inhibits the growth of Staphylococcus aureus with a MIC of 25 μg/mL. Corilagin shows anti-tumor activity on hepatocellular carcinoma and ovarian cancer model. Corilagin shows low toxicity to normal cells and tissues .
    Corilagin (Standard)
  • HY-P10323
    T7 Peptide

    Tumstatin (74-98), human

    		 Integrin FAK mTOR Apoptosis Cancer
    T7 Peptide is a protein synthesis inhibitor and anti-angiogenic agent, with a Kd of 10 nM for human transferrin receptor. T7 Peptide inhibits the phosphorylation of focal adhesion kinase, the activation of phosphatidylinositol 3-kinase and Akt, the kinase activity of mTOR, as well as the phosphorylation of 4E-BP1 in endothelial cells. T7 Peptide induces G0/G1 cell cycle arrest, apoptosis and protective autophagy in hepatocellular carcinoma cells, and suppresses tumor growth in mouse models. T7 Peptide is applicable to research related to cancer, glioblastoma, hepatocellular carcinoma and glioma .
    T7 Peptide
  • HY-P10323A
    T7 Peptide TFA

    Tumstatin (74-98), human TFA

    		 Integrin FAK mTOR Apoptosis Cancer
    T7 Peptide TFA is a protein synthesis inhibitor and anti-angiogenic agent, with a Kd of 10 nM for human transferrin receptor. T7 Peptide TFA inhibits the phosphorylation of focal adhesion kinase, the activation of phosphatidylinositol 3-kinase and Akt, the kinase activity of mTOR, as well as the phosphorylation of 4E-BP1 in endothelial cells. T7 Peptide TFA induces G0/G1 cell cycle arrest, apoptosis and protective autophagy in hepatocellular carcinoma cells, and suppresses tumor growth in mouse models. T7 Peptide TFA is applicable to research related to cancer, glioblastoma, hepatocellular carcinoma and glioma .
    T7 Peptide TFA
  • HY-N6674
    Diazepinomicin

    ECO-4601; TLN-4601; BU 4664L

    		 Apoptosis Bacterial Cathepsin Parasite Endogenous Metabolite Infection Inflammation/Immunology Cancer
    Diazepinomicin (ECO-4601) is an anticancer and antibacterial agent. Diazepinomicin can be produced by a Micromonospora strain. Diazepinomicin induces Apoptosis. Diazepinomicin inhibits the proteases Rhodesain and Cathepsin L at an IC50 of 70-90 μM. Diazepinomicin possesses anti-inflammatory and anti-tumor activity. Diazepinomicin has demonstrated activity against hepatocellular carcinoma. Diazepinomicin shows antiparasitic activity against trypomastigote forms of Trypanosoma brucei with an IC50 of 13.5 μM. Diazepinomicin exhibits moderate antibacterial activity against specific Gram-positive bacteria, with an MIC of approximately 32 μg/mL .
    Diazepinomicin
  • HY-178205
    BPRCX807

    		CXCR ERK Akt Cancer
    BPRCX 807 is a selective and potent CXCR4 (CXC chemokine receptor type 4) antagonist. BPRCX 807 inhibits CXCL12-mediated ERK and Akt phosphorylation. BPRCX 807 can significantly suppress primary tumor growth. BPRCX 807 can be used for the study of hepatocellular carcinoma .
    BPRCX807
  • HY-P11050A
    SP94

    		Apoptosis Cancer
    SP94 is a peptide ligand with high specificity for hepatocellular carcinoma cells. SP94 selectively binds to multiple hepatocellular carcinoma cell lines in vitro. SP94 inhibits tumor growth in a mouse model of hepatocellular carcinoma by promoting apoptosis and reducing angiogenesis. SP94 can be used as a specific probe for hepatocellular carcinoma imaging. SP94 is useful for hepatocellular carcinoma research .
    SP94
  • HY-W440913
    DSPE-PEG5000-Cy5

    		Liposome Fluorescent Dye Cancer
    DSPE-PEG-Cy5, MW 5000 is a fluorescently labeled PEGylated phospholipid with a molecular weight of 5000 Da. After intravenous injection, DSPE-PEG-Cy5, MW 5000 shows only extremely low fluorescence accumulation at tumor sites in orthotopic tumor-bearing mice, and can be used as a negative control for evaluating tumor accumulation of nanoparticles. DSPE-PEG-Cy5, MW 5000 can serve as a fluorescent marker to prepare Cy5-labeled NPs-DPPA and NPs-DPPA (C3F8) for pharmacokinetic and biodistribution studies in mice. DSPE-PEG-Cy5, MW 5000 is widely applicable to research in fields related to triple-negative breast cancer, hepatocellular carcinoma and so on .
    DSPE-PEG5000-Cy5
  • HY-16232
    Glufosfamide

    D 19575; Glucosylifosfamide mustard

    		 Apoptosis Caspase Bcl-2 Family Cancer
    Glufosfamide is a glucose-conjugated alkylating cytotoxic agent and a derivative of Ifosfamide (HY-17419). Glufosfamide induces apoptosis frequency and increase the expression of caspase-9 and caspase-3 in cancer cells. Glufosfamide shows great anti-tumor activity in MiaPaCa-2-RFP mouse model. Glufosfamide can be used for the study of hepatocellular carcinoma, prostate cancer and pancreatic carcinoma .
    Glufosfamide
  • HY-135562
    Ascofuranone

    		Parasite Antibiotic Infection Cancer
    Ascofuranone is an orally active inhibitor of Trypanosoma brucei brucei (TAO) with a Ki value of 2.38 nM. Ascofuranone inhibits IGF-1-induced cancer cell migration, invasion, motility and actin cytoskeleton formation, and exerts anti-tumor effects. Ascofuranone can be used in research related to tumor metastasis, African trypanosomiasis, bacterial infections, lung cancer and hepatocellular carcinoma .
    Ascofuranone
  • HY-176508
    KDX1381

    		Casein Kinase Cancer
    KDX1381 is a bivalent CK2α inhibitor (IC50: 17 nM, KD: 54 nM). KDX1381 has antitumor activity in mouse 786-O and A375 tumor xenograft models. KDX1381 combined with VEGFR inhibitors or DNA damaging agents enhances antitumor efficacy in mouse hepatocellular carcinoma and glioma models .
    KDX1381
  • HY-P5372A
    Ala-parafluoroPhe-Arg-Cha-Cit-Tyr-NH2 TFA

    		Protease Activated Receptor (PAR) Cancer
    Ala-parafluoroPhe-Arg-Cha-Cit-Tyr-NH2 TFA, a bioactive peptide, is a selective Protease activating receptor 1 (PAR-1) agonist over PAR-2. PAR-1 belongs to a subfamily of G-protein coupled receptors and is known to mediate the cellular effects of thrombin. In addition to its varied cellular effects of thrombin, PAR-1 has also been shown to coordinate with PAR-4 and regulate thrombin-induced hepatocellular carcinoma harboring thrombin formation within the tumor environment classified as 'coagulation type' .
    Ala-parafluoroPhe-Arg-Cha-Cit-Tyr-NH2 TFA
  • HY-P10553
    ARF(26–44), cell-permeable

    		Apoptosis Cancer
    ARF(26–44), cell-permeable is a cell-penetrating peptide derived from a specific amino acid sequence of the p14ARF tumor suppressor protein. As a functional inhibitor of FoxM1, ARF(26–44) cell-permeable shows significant anti-tumor activity in the treatment of mouse hepatocellular carcinoma (HCC), significantly increasing tumor cell apoptosis and reducing tumor cell proliferation and angiogenesis. ARF(26–44), cell-permeable can be used in research on tumor therapy .
    ARF(26–44), cell-permeable
  • HY-179395
    TEAD-IN-23

    		YAP Cancer
    TEAD-IN-23 (Compound 22) is an efficient pan-TEAD inhibitor with an IC50 of 10 nM. TEAD-IN-23 exhibits potent anti-proliferative activity in both NCI-H226 and MSTO-211H. TEAD-IN-23 causes complete tumor regression in the MSTO-211H xenograft tumor model. TEAD-IN-23 can be used for the study of mesothelioma and hepatocellular carcinoma .
    TEAD-IN-23
  • HY-151461
    CHNQD-01255

    		Arf Family GTPase Cancer
    CHNQD-01255 is an orally active Arf-GEFs inhibitor with potent anti-hepatocellular carcinoma (HCC) efficacy .
    CHNQD-01255
  • HY-N5014
    Liensinine perchlorate
    Maximum Cited Publications
    20 Publications Verification

    		 Reactive Oxygen Species (ROS) Autophagy Apoptosis VEGFR JAK Amyloid-β p38 MAPK HIF/HIF Prolyl-Hydroxylase STAT PI3K JNK Akt Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
    Liensinine perchlorate is a bisbenzylisoquinoline alkaloid. By inhibiting the PI3K/AKT and JNK/p38-MAPK signaling pathways, Liensinine perchlorate suppresses autophagy and apoptosis, clears Aβ, and exerts anti-inflammatory, antioxidant and neuroprotective effects. Liensinine perchlorate activates AMPK and inhibits the expression of HIF-1α and VEGF, thereby suppressing angiogenesis. Liensinine perchlorate exerts anti-tumor effects through ROS-mediated inhibition of the JAK2/STAT3 signaling pathway. Liensinine perchlorate can be used for the research of diseases such as Alzheimer's disease, hepatocellular carcinoma, osteosarcoma, sepsis-induced organ injury and stroke .
    Liensinine perchlorate
  • HY-160215A
    GFH018 methylbenzenesulfonate

    		TGF-β Receptor p38 MAPK TGF-beta/Smad Interleukin Related Cancer
    GFH018 is an orally active, selective and ATP-competitive TGF-βR1 inhibitor with an IC50 of 40 nM. GFH018 reactivates the immune system by blocking the immunosuppression mediated by regulatory T cells and M2 macrophages. GFH018 inhibits tumor angiogenesis. GFH018 suppresses tumor growth in mouse tumor models. GFH018 can be used for the research of solid tumors, hepatocellular carcinoma, colorectal cancer, breast cancer, and relapsed/metastatic nasopharyngeal carcinoma .
    GFH018 methylbenzenesulfonate
  • HY-177796
    TMLB-C16

    		Apoptosis CDK Caspase PARP Cancer
    TMLB-C16 is a potent and orally active B3GAT3 inhibitor with a KD of 3.962 μM. TMLB-C16 suppresses proliferation and migration, and induces cell cycle arrest and apoptosis in MHCC-97H (IC50 = 6.53 μM) and HCCLM3 cells (IC50 = 6.22 μM). TMLB-C16 inhibits tumor growth in both MHCC-97H and HCCLM3 xenograft tumor mouse models without causing obvious toxicity. TMLB-C16 can be used for hepatocellular carcinoma research .
    TMLB-C16
  • HY-P991566
    KD6001

    		CTLA-4 Cancer
    KD6001 is a humanized IgG1κ monoclonal antibody, targeting CTLA4. KD6001 significantly disrupts CTLA-4 interactions with CD80 (IC50: 16 ng/mL) and CD86. KD6001 enhances IL-2 and IFNγ expression in PHA-activated human lymphocytes and exhibits potent antitumor effects. KD6001 effectively inhibits tumor growth in MC38, B16, and Hepa1-6 tumor mice model. KD6001 can be used for cancers research, such as advanced melanoma, hepatocellular carcinoma and liver cancer .
    KD6001
  • HY-177134
    Taligantinib

    		VEGFR c-Met/HGFR Cancer
    Taligantinib (Compound Example 70) is an orally active and selective dual inhibitor targeting vascular endothelial growth factor receptor 2 (VEGFR-2) and hepatocyte growth factor receptor (c-Met). Taligantinib suppresses tumor angiogenesis and cell proliferation. Taligantinib is promising for research of solid tumors such as non-small cell lung cancer and hepatocellular carcinoma .
    Taligantinib
  • HY-P10553A
    ARF(26–44), cell-permeable acetate

    		Apoptosis Cancer
    ARF(26–44), cell-permeable acetate is a cell-penetrating peptide derived from a specific amino acid sequence of the p14ARF tumor suppressor protein. As a functional inhibitor of FoxM1, ARF(26–44) cell-permeable acetate shows significant anti-tumor activity in the treatment of mouse hepatocellular carcinoma (HCC), significantly increasing tumor cell apoptosis and reducing tumor cell proliferation and angiogenesis. ARF(26–44), cell-permeable acetate can be used in research on tumor therapy .
    ARF(26–44), cell-permeable acetate
  • HY-178098
    TEAD-IN-21

    		YAP Cancer
    TEAD-IN-21 is a potent and orally active pan-TEAD inhibitor with an IC50 of 3 nM. TEAD-IN-21 effectively inhibited the proliferation of Huh-7 cells. TEAD-IN-21 selectively downregulates TEAD-dependent downstream genes. TEAD-IN-21 achieves tumor regression in a liver cancer-derived tumor xenograft mice model. TEAD-IN-21 can be used in the research of hepatocellular carcinoma (HCC) .
    TEAD-IN-21
  • HY-P99881
    Rolinsatamab talirine

    ABBV 176

    		 Antibody-Drug Conjugates (ADCs) Cancer
    Rolinsatamab talirine (ABBV 176) is a prolactin receptor (PRLR)-targeting antibody-drug conjugate (ADC), compoused of Rolinsatamab (HY-P99238) and SGD-1882 (HY-101127). Rolinsatamab talirine binds to PRLR to deliver a cytotoxin to tumor cells. Rolinsatamab talirine induces DNA damage, and exhibits cytotoxicity against multiple breast tumor models, including triple negative and low PRLR-expressing models. Rolinsatamab talirine demonstrates enhanced anti-tumor activity in several breast cancer models. Rolinsatamab talirine can be used for the research of breast cancer, hepatocellular carcinoma, ovarian cancer, endometrial cancer, prostate cancer, colorectal cancer, adrenocortical carcinoma, and solid tumors .
    Rolinsatamab talirine
  • HY-175265
    PQ32

    		c-Myc Ras Apoptosis Cancer
    PQ32 is an antitumor agent that targets c-MYC Pu27 and KRAS G-quadruplexes. PQ32 inhibits tumor cell proliferation, arrests the cell cycle at the G2 phase, and induces apoptosis. PQ32 inhibits the expression of c-MYC and KRAS genes. PQ32 can inhibit tumor growth in mice and is used in the study of lymphoma, breast cancer, lung cancer, hepatocellular carcinoma, colorectal cancer, and other cancers .
    PQ32

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: